natgillin/translations-raw huggingface dataset:
the first nucleic acid, the second nucleic acid, or both nucleic acids are at least 10 kb; and/or 
prva nukleinska kiselina, druga nukleinska kiselina, ili obje nukleinske kiseline imaju najmanje10 kb; i/ili
The method of any preceding claim, wherein at least three nucleic acids are assembled. The method of any preceding claim, wherein: 
Postupak iz bilo kojeg od prethodnih patentnih zahtjeva, naznačen time, što se sastavljaju najmanje tri nukleinske kiseline.
the joiner oligo is from about 100 bp to about 300 bp; and/or 
spojni oligonukleotid ima od oko 100 bp do oko 300 bp; i/ili
introducing into the cell: 
uvođenje u ćeliju:
the first nuclease agent, wherein the first nuclease agent induces a nick or a double-strand break at the first nuclease recognition site, thereby disrupting expression or activity of the first selection marker; and 
prvog sredstva nukleaze, pri čemu prvo sredstvo nukleaze izaziva zarez ili dvolančani prekid na prvom mjestu za prepoznavanje nukleaze, čime se narušava ekspresija ili aktivnost prvog selekcijskog markera; i
a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) protein and a guide RNA (gRNA). 
je okupljena kratkim palindromskim ponavljanjima na jednakim razmacima (CRISPR)-povezan (Cas) protein i vodeća RNK (gRNA).
the first target site and the second target site are about 10 nucleotides to about 14 kb from the first nuclease recognition site; 
prvo ciljno mjesto i drugo ciljno mjesto su oko 10 nukleotida do oko 14 kb od prvog mjesta za prepoznavanje nukleaze;
integration of the first insert polynucleotide into the target locus results in a knockout, a knock-in, a point mutation, a domain swap, an exon swap, an intron swap, a regulatory sequence swap, a gene swap, or a combination thereof; and/or 
integracija prvog umetnutog polinukleotida u ciljni lokus rezultira knockout-om, knock-in-om, točkastom mutacijom, zamjenom domena, zamjenom egzona, zamjenom introna, zamjenom regulatorne sekvence, zamjenom gena, ili njihovom kombinacijom; i/ili
integration of the second insert polynucleotide into the target locus results in a knockout, a knock-in, a point mutation, a domain swap, an exon swap, an intron swap, a regulatory sequence swap, a gene swap, or a combination thereof. 
integracija drugog umetnutog polinukleotida u ciljni lokus rezultira knockout-om, knock-in-om, točkastom mutacijom, zamjenom domena, zamjenom egzona, zamjenom introna, zamjenom regulatorne sekvence, zamjenom gena, ili njihovom kombinacijom.
a hygromycin resistance gene. 
gen za otpornost na higromicin.
The vaccine of claim 1 or 2, wherein the recombinant Mycobacterium bovis cell is characterized as rBCG ΔUrec:: Hly+:: Hyg+. 
Rekombinantna Mycobacterium bovis stanica iz zahtjeva 1 ili 2, koja je okarakterizirana kao rBCG ΔUrec:: Hly+:: Hyg+.
The vaccine of any one of claims 1-4, which is for administration to a Mycobacterium-pre-exposed subject. 
Rekombinantna Mycobacterium bovis stanica iz bilo kojeg od zahtjeva 1-4, za uporabu kao cjepivo na ljudskim ispitanicima.
in a buffer solution, said buffer solution preferably comprising acetate, citrate, prolamine, carbonate, or phosphate or any combination thereof, more preferably phosphate buffered saline (PBS). 
s otopinom pufera, pri čemu poželjno navedena otopina pufera sadrži acetat, citrat, prolamin, karbonat, ili fosfat ili bilo koju njihovu kombinaciju, pri čemu je još poželjnije da je puferska otopina fiziološka otopina puferirana fosfatima (PBS); ili
The RNAi agent for use of claim 10, wherein said subject carries a TTR gene mutation that is associated with the development of a TTR-associated disease. The RNAi agent for use of any one of claims 10 to 13, wherein said TTR-associated disease is selected from the group consisting of senile systemic amyloidosis (SSA), systemic familial amyloidosis, familial amyloidotic polyneuropathy (FAP), familial amyloidotic cardiomyopathy (FAC), leptomeningeal/Central Nervous System (CNS) amyloidosis, and hyperthyroxinemia. 
Sredstvo ili pripravak za uporabu prema bilo kojem od patentnih zahtjeva 11 do 14, naznačeni time što se navedeni subjekt nosi mutaciju gena TTR koja je povezana s razvojem bolesti povezane s, pri čemu je poželjno navedena bolest povezana s TTR odabrana iz skupine koja sadrži senilnu sistemsku amiloidozu (SSA), sistemsku obiteljsku amiloidozu, obiteljsku amiolidotičnu polineuropatiju (FAP), obiteljsku amiolidotičnu kardiomiopatiju (FAC), leptomeningealnu amiloidozu / amiloidozu središnjeg živčanog sustava (CNS), i hipertiroksinemiju.
A soft capsule consisting of a gelatin-based shell and a filling of said shell, said filling comprising a solution, suspension or dispersion of active principles, said active principles being: 
Meka kapsula koja se sastoji od školjke na bazi želatine i punjenja navedene školjke, pri čemu navedeno punjenje sadrži otopinu, suspenziju ili disperziju aktivnih načela, pri čemu su navedeni aktivni principi:
The soft capsule according to any one of the preceding claims, for use in the treatment and/or prevention of polycystic ovary syndrome, insulin resistance, hyperinsulinemia, hyperglycemia, hyperandrogenism, metabolic syndrome, dyslipidemia, type 2 diabetes mellitus and cardiovascular/cerebrovascular diseases, in Medically Assisted Procreation (MAP) therapies in order to improve oocyte quality, and to optimize ovarian hyperstimulation protocols; in particular to prevent ovarian hyperstimulation syndrome, irritability, hypertension, osteoporosis, dyslipidemia, weight gain, hot flushes and aging of the skin. 
Meka kapsula prema bilo kojem od prethodnih zahtjeva, naznačena time, da se upotrebljava za liječenje i / ili sprječavanje sindroma policističnih jajnika, inzulinske rezistencije, hiperinzulinemije, hiperglikemije, hipendrondrogenizma, metaboličkog sindroma, dylidididemije, šećerne bolesti tipa 2 i kardiovaskularnog / cerebrovaskularne bolesti, u terapiji medicinski potpomognute oplodnje (MAP) radi poboljšanja kvalitete oocita i optimizacije protokola hiperstimulacije jajnika; posebno za sprječavanje sindroma hiperstimulacije jajnika, razdražljivosti, hipertenzije, osteoporoze, dislipidemije, debljanja, vrućice i starenja kože.
step c) amination of a compound of formula (IV) to form a compound of formula (V) 
Korak b) Aminacija spoja formule (IV) u svrhu tvorbe navedenog spoja formule (V) [image]
A process according to claim 1, wherein step a) is performed with an oxidant at a reaction temperature range between 0° C. and 100° C. 
Postupak prema patentnom zahtjevu 1, naznačen time, da se korak a) izvodi s azidnim reagensom i bazom u organskom otapalu, nakon čega slijedi dodavanje alkohola u temperaturnom rasponu od 0 °C do 100 °C.
trace elements. 
elemenata u tragovima.
hormones and other growth factors; 
hormona i drugih faktora rasta;
The process of any one of claims 1 to 13 wherein the polypeptide is a mammalian glycoprotein; or is selected from the group consisting of antibodies, antibody fragments, and immunoadhesins. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je polipeptid odabran iz skupine koja se sastoji od protutijela, fragmenata protutijela i imunoadhezina.
The process of claim 14 wherein said antibody fragment is selected from the group consisting of Fab, Fab', F(ab')2, scFv, (scFv)2, dAb, complementarity determining region (CDR) fragments, linear antibodies, single-chain antibody molecules, minibodies, diabodies, and multispecific antibodies formed from antibody fragments. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time, da je navedeni fragment protutijela odabran iz skupine koja se sastoji od Fab, Fab', F(ab')2, scFv, (scFv)2, dAb, fragmenata regija koje određuju komplementarnost (CDR), linearnih protutijela, jednolančanih molekula protutijela, minitijela, dijatijela i multispecifičnih protutijela nastalih iz fragmenata protutijela.
or R1 and R1', or R2 and R2', together with the atom to which they are attached, can combine to form -(C3-C8)cycloalkyl ring, heterocycle, (C5-C8)spirocycle or 5-to 8-membered spiroheterocycle; 
ili R1 i R1’, ili R2 i R2’, zajedno s atomom za koji su vezani, mogu se kombinirati da bi formirali -(C3-C8) cikloalkilni prsten, heterocikl, (C5-C8)spirocikl ili 5-do 8-člani spiroheterocikl;
or R1 and R2, together with the atoms to which they are attached, can combine to form a - (C3-C8)cycloalkyl or a 3-to 8-membered heterocycle; 
ili R1 i R2, zajedno s atomima za koje su vezani, mogu se kombinirati da bi formirali -(C3-C8)cikloalkil ili 3-do 8-člani heterocikl;
or R2 and R3, together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring; 
ili R2 i R3, zajedno s atomima za koje su vezani, mogu se kombinirati da bi formirali 5- do 8-člani heterociklični prsten;
or R1 and R3, together with the atoms to which they are attached, can combine to form a 5- to 8-membered heterocyclic ring, optionally fused to an aryl or heteroaryl ring; 
ili R1 i R3, zajedno s atomima za koje su vezani, mogu se kombinirati da bi formirali 5- do 8-člani heterociklični prsten, opcionalno spojen s aril ili heteroaril prstenom;
The compound of claim 1 or claim 4, wherein R1 and R1' are each independently hydrogen, optionally substituted-(C1-C6)alkyl, optionally substituted aryl, or optionally substituted heteroaryl, or wherein R1 and R1', taken together with the atoms to which they are attached, combine to form an optionally substituted -(C3-C4)cycloalkyl. 
Spoj prema zahtjevu 1 ili zahtjevu 4, gdje R1 i R1’ su svaki nezavisno vodik, opcionalno supstituirani –(C1-C6)alkil, opcionalno supstituirani aril, ili opcionalno supstituirani heteroaril, ili gdje R1 i R1’, uzeti zajedno s atomima za koje su vezani, mogu se kombinirati da formiraju opcionalno supstituirani –(C3-C4)cikloakil.
Y, if present, is a bond; 
Y, ako je prisutan, je veza;
is selected from the group consisting of hydrogen, optionally substituted-(C1-C6)alkyl, optionally substituted aryl, and optionally substituted heteroaryl; 
je izabran iz grupe koja se sastoji od vodika, opcionalno supstituiranog -(C1-C6)alkila, opcionalno supstituiranog arila, i opcionalno supstituiranog heteroarila;
R1', if present, is selected from the group consisting of hydrogen, and optionally substituted -(C1-C6)alkyl; 
’, ako je prisutan, je izabran iz grupe koja se sastoji od vodika, i opcionalno supstituiranog -(C1-C6)alkila;
or R1 and R1', taken together with the atoms to which they are attached, combine to form an optionally substituted -(C3-C4)cycloalkyl; 
ili R1 i R1’, uzeti zajedno s atomima za koje su vezani, mogu se kombinirati da bi formirali opcionalno supstituirani-(C3-C4)cikloalkil;
or R1 and R3, taken together with the atoms to which they are attached, combine to form an optionally substituted 5- to 6-membered heterocyclic ring; 
ili R1 i R3, uzeti zajedno s atomima za koje su vezani, mogu se kombinirati da bi formirali opcionalno supstituirani 5- do 6-člani heterociklični prsten;
is selected from the group consisting of hydrogen, methyl optionally substituted with - OR5, ethyl, optionally substituted 6-membered aryl, and optionally substituted 5- to 6-membered heteroaryl; 
je izabran iz grupe koja se sastoji od vodika, metila opcionalno supstituiranog s –OR5, etil, opcionalno supstituirani 6-članim arilom, i opcionalno supstituirani 5- do 6-člani heteroaril;
or R1 and R1', taken together with the atoms to which they are attached, combine to form an optionally substituted cyclopropyl; 
ili R1 i R1’, uzeti zajedno s atomima za koje su vezani, mogu se kombinirati da bi formirali opcionalno supstituirani ciklopropil;
or R1 and R3, taken together with the atoms to which they are attached, combine to form an optionally substituted 5- to 6-membered heterocyclic ring; 
ili R1 i R3, uzeti zajedno s atomima za koje su vezani, mogu se kombinirati da bi formirali opcionalno supstituirani 5 do 6-očlani heterociklični prsten;
The compound of claim 1 selected from the group consisting of: 
Spoj prema zahtjevu 1 izabran iz grupe koju čine:
A pharmaceutical composition, comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, koja sadrži spoj prema zahtjevu 1 ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač.
An image filtering device for receiving a deblocked decoded image and adding an offset to a pixel value of a pixel of a unit area of the deblocked decoded image which includes a plurality of unit areas, comprising: 
Uređaj za filtriranje slike za primanje deblokirane dekodirane slike i dodavanje offset-a vrijednosti piksela za svaki piksel jedinične površine deblokirane dekodirane slike koja je sastavljena od mnoštva jediničnih površina, koji sadrži:
an offset attribute setting section configured to set an offset bit depth and an offset value range based on coded data, wherein a maximum bit length representing the offset value range is equal to the offset bit depth-K, and the value of K is equal to 4; 
jedinicu za postavljanje atributa offset-a konfiguriranu za određivanje dubine bita u skladu s dubinom bita za vrijednosti piksela za daljnje određivanje raspona vrijednosti offset-a i određivanje vrijednost pomaka upućivanjem na vrstu offset-a koja navodi informaciju sadržanu u kodiranim podacima, pri čemu je maksimalna duljina bita koja predstavlja raspon vrijednosti offset-a jednaka dubini offset bita-K, a vrijednost K jednaka je 4;
an offset decoding section configured to decode an offset which is restricted to a value within the offset value range; 
jedinicu za dekodiranje offset-a konfiguriranu za dekodiranje offset-a koja je ograničena na raspon vrijednosti offset-a;
A filtering method for receiving a deblocked decoded image and adding an offset to a pixel value of a pixel of a unit area of the deblocked decoded image which includes a plurality of unit areas, comprising: 
Postupak filtriranja za primanje deblokirane dekodirane slike i dodavanje offset vrijednosti piksela za svaki piksel jedinične površine deblokirane dekodirane slike koja je sastavljena od mnoštva jediničnih površina, koji sadrži:
setting an offset bit depth and an offset value range based on coded data, wherein a maximum bit length representing the offset value range is equal to the offset bit depth-K, and the value of K is equal to 4; decoding an offset which is restricted to the offset value range; and 
određivanje dubine offset bita u skladu s dubinom bita za vrijednosti piksela radi daljnjeg određivanja raspona vrijednosti offset-a i određivanje vrijednosti pomaka upućivanjem na vrstu offset-a koja navodi informacije uključene u kodirane podatke, pri čemu je maksimalna duljina bita koja predstavlja raspon vrijednosti offset-a jednaka dubini offset bita-K, a vrijednost K jednaka je 4;
The antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof is formulated for topical, intraocular, oral, nasal, rectal or parental administration. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da je protutijelo ili njegov ulomak koji veže antigen formulirano za topikalnu, intraokularnu, oralnu, nazalnu, rektalnu ili parenteralnu primjenu.
and/or in the process for preparing compound 4, the alcohol solvent is methanol; 
i / ili u postupku pripreme spoja 4, alkoholno otapalo je metanol;
and/or in the process for preparing compound 4, the ratio of the volume of the alcohol solvent to the mole of compound 5 is in the range of 1-10 L/mol; 
i / ili u postupku pripreme spoja 4, omjer volumena alkoholnog otapala prema molu spoja 5 je u rasponu od 1-10 L/mol;
and/or in the process for preparing compound 4, the mole ratio of [Rh(Duanphos)(X)]Y to compound 5 is in the range of 0.00001-0.01; 
i / ili u postupku pripreme spoja 4, molni omjer [Rh(Duanphos)(X)]Y i spoja 5 je u rasponu 0,00001-0,01;
and/or in the process for preparing compound 4, the hydrogenation temperature is in the range of 20-30° C.; 
i / ili u postupku pripreme spoja 4, temperatura hidrogeniranja je u rasponu od 20-30°C;
and/or in the process for preparing compound 4, the reaction time for hydrogenation is 4-8 h. 
i / ili u postupku pripreme spoja 4, reakcijsko vrijeme hidrogeniranja je 4-8 h.
The process defined as claim 2, wherein the pressure of hydrogen is in the range of 0.5-3.0 MPa; and/or in the process for preparing compound 4, the ratio of the volume of the alcohol solvent to the mole of compound 4 is in the range of 1.5-3 L/mol; 
Postupak prema zahtjevu 2, naznačen time, da je tlak vodika u rasponu od 0,5-3,0 MPa, poželjno 1,5-2,0 MPa; i / ili u postupku pripreme spoja 4, omjer volumena alkoholnog otapala prema molu spoja je u rasponu od 1,5-3 L/mol, poželjno 2,3-2,8 L/mol;
and/or in the process for preparing compound 4, the mole ratio of [Rh(Duanphos)(X)]Y to compound 5 is in the range of 0.0001-0.0003; 
i / ili u postupku pripreme spoja 4, molni omjer [Rh(Duanphos)(X)]Y i spoja 5 je u rasponu od 0,0001-0,0003, poželjno 0,00025-0,000265;
According to the process defined as claim 1, wherein in the preparation of compound 5, the reaction solvent is selected from the group consisting of haloalkanes, nitriles, alcohols, ethers and any combination thereof; 
Postupak prema zahtjevu 4, naznačen time da se za pripremu spoja 5 odabire reakcijsko otapalo iz skupine koja se sastoji od haloalkana, nitrila, alkohola, etera i bilo koje kombinacije istih;
and/or in the preparation of compound 5, the base is one of the common bases used for this transformation or any combination thereof, which is selected from the group consisting of tetramethylguanidine, sodium methoxide, sodium ethoxide, sodium hydroxide, sodium hydride, sodium amide and DBU; 
i / ili u pripremi spoja 5, baza je jedna od uobičajenih baza korištenih za ovu transformaciju ili bilo koja druga njihova kombinacija, koja je odabrana iz skupine koja sadrži tetrametilguanidin, natrijev metoksid, natrijev etoksid, natrijev hidroksid, natrijev hidrid, natrijev amid i DBU;
and/or in the preparation of compound 5, the reaction temperature for condensation is in the range of 0-40° C.; 
i / ili u pripremi spoja 5, reakcijska temperatura za kondenzaciju je u rasponu od 0-40°C;
and/or, in the preparation of compound 5, the reaction time for condensation is 4-6 h. 
i / ili, u pripremi spoja 5, reakcijsko vrijeme kondenzacije je 4-6 h.
The process defined as claim 5, wherein in the preparation of compound 5, the haloalkane solvent is dichloromethane; 
Postupak prema zahtjevu 5, naznačen time da je u pripremi spoja 5 haloalkansko otapalo diklormetan;
and/or, in the preparation of compound 5, the nitrile solvent is acetonitrile; 
i / ili u pripremi spoja 5, nitrilno otapalo je acetonitril;
and/or, in the preparation of compound 5, the alcohol solvent is methanol and/or ethanol; 
i / ili u pripremi spoja 5, alkoholno otapalo je metanol i / ili etanol;
and/or, in the preparation of compound 5, the ether solvent is methyl tent-butyl ether; 
i / ili u pripremi spoja 5, etersko otapalo je metil-terc-butil eter;
A process for preparing compound 2, which comprises: 
Postupak za pripremu spoja 2, koji se sastoji od:
in the presence of a base, reacting compound 4 with di-tert butyl dicarbonate to form compound 3; 
. u prisutnosti baze, reakcijski spoj 4 s di-terc-butil-dikarbonatom tvori spoj 3;
The process defined as claim 7, wherein in step (2), a reaction solvent is selected from the group consisting of haloalkanes, nitriles, alcohols, ethers, pyridine, NMP and any combination thereof; 
Postupak prema zahtjevu 7, naznačen time da se u koraku (2) odabire reakcijsko otapalo iz skupine koja sadrži haloalkane, nitrile, alkohole, etere, piridin, NMP i bilo koju njihovu kombinaciju;
and/or, in step (2), the ratio of the volume of the solvent to the mole of compound 4 is in the range of 1-6 L/mol; 
i / ili, u koraku (2), omjer volumena otapala prema molu spoja 4 je u rasponu od 1-6 L/mol;
and/or, in step (2), the mole ratio of the base to compound 4 is in the range of 0.12-0.18; 
i / ili, u koraku (2), molni omjer baze prema spoju 4 je u rasponu 0,12-0,18;
and/or, in step (2), the mole ratio of di-tent butyl dicarbonate to compound 4 is in the range of 1.5-1.8; 
i / ili, u koraku (2), molni omjer di-terc-butil-dikarbonata prema spoju 4 je u rasponu 1,5-1,8;
and/or, in step (2), the alcohol solvent is methanol; 
i / ili, u koraku (2) alkoholno otapalo je metanol;
and/or, in step (2), the ratio of the volume of the organic solvent to the mole of compound 4 is in the range of 2-3 L/mol; 
i / ili, u koraku (2), omjer volumena organskog otapala prema molu spoja 4 je u rasponu 2-3 L/mol;
and/or, in step (2), the inorganic base is sodium bicarbonate and/or sodium carbonate; 
i / ili, u koraku (2), anorganska baza je natrijev bikarbonat i / ili natrijev karbonat;
preparing compound 2 according to the process defined as claim 10; 
pripreme spoja 2 prema postupku definiranom prema barem jednom od zahtjeva 10 do 13;
in an organic solvent, reacting compound 3 with hydrazine to afford compound 2; 
u organskom otapalu, reagiranja spoja 3 s hidrazinom, da se dobije spoj 2;
The process defined as claim 10, wherein in step (b), the organic solvent is selected from the group consisting of haloalkanes, nitriles, alcohols, ethers, pyridine and NMP and any combination thereof; 
Postupak prema zahtjevu 10, naznačen time da se u koraku (b) organsko otapalo bira iz skupine koja se sastoji od haloalkana, nitrila, alkohola, etera, piridina i NMP-a i bilo koje njihove kombinacije;
and/or, in step (b), the ratio of the volume of the solvent to the mole of compound 3 is in the range of 2-3 L/mol; 
i / ili, u koraku (b), omjer volumena otapala prema molu spoja 3 je u rasponu od 2-3 L/mol;
and/or, in step (b) which is hydrazinolysis, the hydrazine is added in the form of hydrazine hydrate; 
i / ili, u koraku (b) koji je hidrazinoliza, hidrazin se dodaje u obliku hidrazin hidrata;
and/or, in step (b) which is hydrazinolysis, the mole ratio of hydrazine to compound 3 is in the range of 2.8-3.5; 
i / ili u koraku (b) koji je hidrazinoliza, molni omjer hidrazina prema spoju 3 je u rasponu 2,8-3,5;
and/or, in step (b), the reaction temperature for hydrazinolysis is in the range of 0-10° C.; 
i / ili, u koraku (b), reakcijska temperatura za hidrazinolizu je u rasponu od 0-10°C;
and/or, in step (b), the alcohol solvent is methanol; 
i / ili, u koraku (b), alkoholno otapalo je metanol;
The process defined as claim 10, wherein compound 3 is not necessary to be isolated when step (a) is completed, which means there is no need to isolate and purify compound 3, which is used directly for step (b). A process for preparing N-Boc biphenyl alaninol, which comprises: 
Postupak prema barem jednom od zahtjeva 10 do 12, naznačen time da spoj 3 nije potrebno izolirati kad je korak (a) dovršen, što znači da nema potrebe za izoliranjem i pročišćavanjem spoja 3, koji se koristi izravno za korak (b).
The process defined as claim 14, wherein in step (b) of preparing compound 1, the ratio of the volume of methanol and/or ethanol to the mole of compound 2 is in the range of 2-4 L/mol; 
Postupak prema zahtjevu 14, naznačen time da je u koraku (b) pripreme spoja 1, omjer volumena metanola i / ili etanola na mol spoja 2 je u rasponu 2-4 L/mol, poželjno 2,1-3,0 L/mol;
and/or, in step (b) of preparing compound 1, the metal borohydride is selected from the group consisting of sodium borohydride, potassium borohydride, lithium borohydride, and any combination thereof; 
i / ili, u koraku (b) pripreme spoja 1, metalni borohidrid je odabran iz skupine koja se sastoji od natrijevog borohidrida, kalijevog borhidrida, litijevog borohidrida i bilo koje njihove kombinacije;
and/or, in step (b) of preparing compound 1, the mole ratio of metal borohydride to compound 2 is in the range of 2.0-4.0; 
i / ili, u koraku (b) pripreme spoja 1, molni omjer metalnog borohidrida i spoja 2 je u rasponu od 2,0-4,0, poželjno 2,9-3,1;
and/or, in step (b) of preparing compound 1, the reaction temperature for reduction is 15-30° C.; 
i / ili, u koraku (b) pripreme spoja 1, reakcijska temperatura za redukciju je 15-30°C, poželjno 25-30°C;